Is there an optimal dose and formulation of aspirin to prevent arterial thrombo-embolism in man?
D001241:Aspirin / Q000008:administration & dosage* / Q000627:therapeutic use; D001792:Blood Platelets / Q000378:metabolism; D001808:Blood Vessels / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control; D010974:Platelet Aggregation / Q000187:drug effects; D011247:Pregnancy; D013923:Thromboembolism / Q000517:prevention & control*; D013928:Thromboxane A2 / Q000096:biosynthesis
D016861:Cyclooxygenase Inhibitors; D013928:Thromboxane A2; D011464:Epoprostenol; D001241:Aspirin